The American Cancer Society Awards $2.1 Million to Montefiore Einstein Cancer Center to Support Cancer Research and Tackle Inequities
Summary
The ACS support assists her lab in determining if crizotinib prevents out-of-control blood-cell division in mouse models of MPN, with the goal of moving the drug swiftly into clinical trials. In addition, she will investigate a protein inhibited by crizotinib, RON kinase, as a new target for MPN.Addressing Socioeconomic BarriersThe ACS grants will also enable MECC to add navigators to streamline appointments, such as imaging studies, lab assessments and treatments, for individuals with locally advanced, non-metastatic cancer who would benefit from neoadjuvant therapy (NAT), which is intended to shrink a tumor prior to surgery. "By deepening our partnership with the ACS, were advancing our ability to recognize infrastructural biases, identify new treatments relevant to our community and provide the very best support to our patients and their families. "The ACS funding is also helping MECC tackle transportation barriers, which are strongly associated with no-show visits, and is adding more free cancer screenings and continuing education courses for doctors and nurses aimed at improving racial equity. We invest in lifesaving research, provide 24/7 information and support, and work to ensure that individuals in every community have access to cancer prevention, detection, and treatment.